Rodman & Renshaw Initiates Hemab Therapeutics at Buy
Rodman & Renshaw initiated coverage of Hemab Therapeutics with a Buy rating and set a $56.00 per-share price target, Benzinga reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Rodman & Renshaw has initiated coverage of Hemab Therapeutics with a Buy rating, according to Benzinga. The ratings update was published on October 12, 2026, at 17:22 GMT.
The research firm also set a price target of $56.00 per share for Hemab Therapeutics. Benzinga’s report lists the company under the ticker COAG.
why it matters
The analyst action gives investors a new published assessment of Hemab Therapeutics and highlights the $56.00 target as a reference point for the company’s shares.
instruments
sources
- Hemab Therapeutics Price Target Announced at $56.00/Share by Rodman & Renshaw — Newsmetry API, 12 October 2026 at 17:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗